Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.

Autor: Tchou J; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Julia.tchou@pennmedicine.upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Julia.tchou@pennmedicine.upenn.edu., Gottipati S; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Goldbach M; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Baxter M; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Venters S; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Balassanian R; Department of Pathology, University of California San Francisco, San Francisco, CA, USA., Vohra P; Department of Pathology, University of California San Francisco, San Francisco, CA, USA., Gonzalves D; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Ahmad Z; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Nayak A; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Boughey JC; Department of Surgery, Mayo Clinic, Rochester, MN, USA., Mukhtar RA; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Chen YY; Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
Jazyk: angličtina
Zdroj: Annals of surgical oncology [Ann Surg Oncol] 2024 Nov; Vol. 31 (12), pp. 8093-8101. Date of Electronic Publication: 2024 Aug 08.
DOI: 10.1245/s10434-024-15889-3
Abstrakt: Background: Rates of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) for breast cancer have improved, especially among human epidermal growth factor 2-positive (HER2+) and triple-negative subtypes. The frequency and significance of biomarker profile change in residual disease are unclear. This study aimed to determine the rate of biomarker profile changes after NAC and the impact on clinical outcomes in a contemporary cohort.
Methods: Upon institutional review board approval, the study identified 634 consecutive patients treated with NAC between 2010 and 2022 at two academic institutions. The study cohort was focused on patients with residual disease who underwent biomarker profile retesting. Biomarker profile change for each subtype was compared across groups using Fisher-Irwin tests. Cox Proportional Hazards Model and Kaplan-Meier plots were performed to evaluate the association of changed versus unchanged biomarker profile with event-free survival.
Results: Biomarker retesting was performed for 259 (61.4 %) of 422 patients with residual disease. Biomarker profile change occurred in 18.1 % overall and was significantly higher among those with pre-NAC HER2+ disease (32.7 %, 17/52) than among those with HER2-disease (14.5 %, 30/207) (p = 0.004). Conversion of pre-NAC biomarker profiles of HR+HER2- and HR+HER2+ to triple-negative breast cancer (TNBC) post-NAC may be associated with worse event-free survival, hazard ratios of 2.23 (95 % confidence interval [CI], 0.90-5.53; p = 0.08), trending toward significance, and 36.7 (95 % CI, 2.2-610.8; p = 0.01), respectively.
Conclusions: The results from one of the largest contemporary cohorts demonstrated that biomarker profile change in patients with residual disease after NAC was common. Furthermore, specific biomarker profile change in residual disease may have prognostic value. These findings strengthen the rationale for routine re-testing of biomarkers in residual disease after NAC.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: